Systems biology based miRNA-mRNA expression pattern analysis of Emodin in breast cancer cell lines.
Breast cancer
Emodin
Estrogen receptor
Phytoestrogen
Systems biology
miRNA
Journal
Pathology, research and practice
ISSN: 1618-0631
Titre abrégé: Pathol Res Pract
Pays: Germany
ID NLM: 7806109
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
30
03
2023
revised:
20
07
2023
accepted:
21
08
2023
medline:
12
9
2023
pubmed:
27
8
2023
entrez:
26
8
2023
Statut:
ppublish
Résumé
Breast cancer has been among the most prominent cancers with high mortality. Currently most of the offered therapeutics are toxic; hence, less toxic therapeutic intervention is required. Here, we studied the molecular mechanisms of the effect of a phytoestrogen Emodin on estrogen receptor positive MCF-7 and negative MDA-MB-231 cells by carrying out a comprehensive network assessment. Differentially expressed microRNAs along with their previously identified differentially expressed mRNAs were analyzed through microarrays by using integrative systems biology approach. For each cell line miRNA-target gene networks were built, gene ontology and pathway enrichment analyses were performed, enrichment maps were constructed and the potential key genes, miRNAs and miRNA-gene interactions were studied.
Identifiants
pubmed: 37633004
pii: S0344-0338(23)00480-6
doi: 10.1016/j.prp.2023.154780
pii:
doi:
Substances chimiques
MicroRNAs
0
Emodin
KA46RNI6HN
RNA, Messenger
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
154780Informations de copyright
Copyright © 2023. Published by Elsevier GmbH.
Déclaration de conflit d'intérêts
Declaration of Competing Interest All of the authors have approved the contents of this paper and have agreed to the ‘Pathology - Research and Practice’ submission policies. Furthermore, each named author has substantially contributed to conducting the underlying research and they have no conflict of interest, financial or otherwise. The authors declare there are no conflicts of interest.